Vical Rolls Out RapidResponse to Accelerate Vaccine Production
Vical Incorporated (San Diego, CA, www.vical.com) has introduced a cell-free manufacturing process designed to produce large quantities of vaccine in a matter of days, compared with the several months required for conventional vaccine production.
Vical Incorporated (San Diego, CA, www.vical.com) has introduced a cell-free manufacturing process designed to produce large quantities of vaccine in a matter of days, compared with the several months required for conventional vaccine production. The RapidResponse DNA platform is intended to significantly reduce the time required to develop, manufacture, and deploy vaccines against emerging diseases during the early stages of an infectious outbreak. The company believes that the RapidResponse DNA platform can overcome the time, capacity, and cost challenges of manufacturing conventional vaccines, which use killed or disabled viruses grown in chicken eggs or via cell culture, requiring months of production time in large facilities. Vical has also been awarded a three-year, $6 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for further development of this manufacturing process.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
